While most people don’t choose a healthcare career to drive profits, many soon realize that it’s impossible to support high-quality care without having a clear understanding of the financial realities of the business. This…
Continue Reading
Hemophilia A patients manage the chronic disorder with infusions administered as frequently as every two to three days. The FDA has approved a Sanofi drug designed to last longer in the body, giving patients…
Continue Reading
AbbVie turned to Capsida Biotherapeutics two years ago for help delivering gene therapies into the brain. That partnership is ongoing, but the pharmaceutical giant now wants to leverage its partner’s technology for delivery of…
Continue Reading
Editor’s note: This story is based on an interview at Abarca Forward, a conference that was hosted by Abarca Health, a pharmacy benefit manager last week in San Juan, Puerto Rico. MedCity News’ Editor-in-Chief…
Continue Reading
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
Copenhagen-based digital health company Dawn Health announced a strategic partnership with pharma giant Novartis to develop a chronic condition management platform. Under the collaboration, Dawn and Novartis will build remote monitoring and management tools for…
Continue Reading
What You Should Know:– Vysioneer, a provider of applied AI for Oncology, today announced a data-sharing agreement with Pfizer, a global leader in pharmaceuticals. The agreement aims to lay the foundation for the application…
Continue Reading
Travere Therapeutics has won FDA approval for a drug that treats a rare autoimmune disorder that is typically first noticed as blood in the urine and can progress over time to end-stage kidney failure.
The…
Clotting disorders can be treated by infusing patients with clotting proteins they lack, or with drugs that replace the function of these proteins. Gene therapies may soon become another option. Hemophilia A and B…
Continue Reading
Editor’s note: This story is based on discussions at Abarca Forward, a conference in San Juan, Puerto Rico, hosted by Abarca Health, a pharmacy benefit manager. MedCity News’ Editor-in-Chief Arundhati Parmar and Senior Reporter Katie Adams were invited to attend and speak at the conference. All travel and related expenses for…
Continue Reading
